MSD förvärvar ny B-cellsterapi, från Curon Biopharmaceutical
MSD utökar sitt utbud av potentiella behandlingar genom att köpa CN201, en ny läkemedelskandidat som kan ha en viktig roll vid behandling av vissa typer av cancer (B-cellsbaserade maligniteter som lymfom och leukemi) och autoimmuna sjukdomar. Läkemedlet har visat lovande tidiga resultat i kliniska studier, och kan, om det fortsätter att visa positiva resultat, leda till effektiva behandlingar för svårbehandlade B-cellsrelaterade sjukdomar.
Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases.
“By actively depleting B-cells, CN201 offers applications spanning both B-cell malignancies and autoimmune diseases. We look forward to building upon the foundational work started by the Curon team,” said Dr. Dean Y. Li, president, Merck Research Laboratories.
CN201 is currently being investigated in Phase 1 and Phase 1b/2 clinical trials for the treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively. Preliminary data suggest CN201 has activity in patients with relapsed or refractory B-cell hematologic malignancies and is well tolerated, potentially leading to significant and sustained reductions in B-cell populations.
